Mexiletine rescues a mixed biophysical phenotype of the cardiac sodium channel arising from the SCN5A mutation, N406K, found in LQT3 patients

Channels (Austin). 2018;12(1):176-186. doi: 10.1080/19336950.2018.1475794.

Abstract

Introduction: Individual mutations in the SCN5A-encoding cardiac sodium channel α-subunit usually cause a single cardiac arrhythmia disorder, some cause mixed biophysical or clinical phenotypes. Here we report an infant, female patient harboring a N406K mutation in SCN5A with a marked and mixed biophysical phenotype and assess pathogenic mechanisms.

Methods and results: A patient suffered from recurrent seizures during sleep and torsades de pointes with a QTc of 530 ms. Mutational analysis identified a N406K mutation in SCN5A. The mutation was engineered by site-directed mutagenesis and heterologously expressed in HEK293 cells. After 48 hours incubation with and without mexiletine, macroscopic voltage-gated sodium current (INa) was measured with standard whole-cell patch clamp techniques. SCN5A-N406K elicited both a significantly decreased peak INa and a significantly increased late INa compared to wide-type (WT) channels. Furthermore, mexiletine both restored the decreased peak INa of the mutant channel and inhibited the increased late INa of the mutant channel.

Conclusion: SCN5A-N406K channel displays both "gain-of-function" in late INa and "loss-of-function" in peak INa density contributing to a mixed biophysical phenotype. Moreover, our finding may provide the first example that mexiletine exerts a dual rescue of both "gain-of-function" and "loss-of-function" of the mutant sodium channel.

Keywords: Mexiletine; SCN5A; mixed phenotype; mutation; sodium channel.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Arrhythmia Agents / pharmacology*
  • Cardiac Conduction System Disease / drug therapy*
  • Cardiac Conduction System Disease / genetics*
  • Cardiac Conduction System Disease / metabolism
  • Female
  • HEK293 Cells
  • Humans
  • Infant
  • Long QT Syndrome / drug therapy*
  • Long QT Syndrome / genetics*
  • Long QT Syndrome / metabolism
  • Mexiletine / pharmacology*
  • Mutation
  • NAV1.5 Voltage-Gated Sodium Channel / genetics*
  • NAV1.5 Voltage-Gated Sodium Channel / metabolism*
  • Phenotype

Substances

  • Anti-Arrhythmia Agents
  • NAV1.5 Voltage-Gated Sodium Channel
  • SCN5A protein, human
  • Mexiletine

Supplementary concepts

  • Long QT syndrome type 3

Grants and funding

This work was supported by an American Heart Association (0525806Z and 11SDG7470009 to B.-H. Tan), Beijing Natural Science Foundation (7184213 to R.-M. Hu) and the National Heart, Lung, and Blood Institute (HL-71092 to J. C. Makielski and HL-42569 to M. J. Ackerman).